| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1080.7B | ¥1054.2B | +2.5% |
| Operating Income | ¥110.9B | ¥38.3B | +189.2% |
| Ordinary Income | ¥131.6B | ¥56.3B | +133.6% |
| Net Income | ¥96.0B | ¥18.4B | +421.6% |
| ROE | 7.9% | 1.6% | - |
FY2025 Q3 cumulative results (9 months ended December 31, 2024): Revenue ¥108.1B (YoY +2.5%), Operating Income ¥11.1B (YoY +189.2%), Ordinary Income ¥13.2B (YoY +133.6%), Net Income ¥9.6B (YoY +421.6%). The company achieved substantial profitability improvement driven by operating margin expansion from 3.6% to 10.3%, representing a 670bp improvement. Net profit margin improved from approximately 1.7% to 8.9%, reflecting enhanced operational efficiency and favorable non-operating factors including FX gains of ¥1.9B. The Organic Chemistry segment was the primary driver of profit growth, with segment profit expanding to ¥10.3B. Cash position strengthened significantly to ¥35.0B (+40.1% YoY), supporting a robust liquidity profile with current ratio of 315.8%. Progress against full-year guidance is on track, with Q3 representing 69.9% of revenue forecast and 65.2% of operating income forecast.
Revenue increased 2.5% YoY to ¥108.1B, with Organic Chemistry segment growing 14.6% to ¥55.4B while Inorganic Chemistry segment declined 7.9% to ¥49.6B. By geography, Europe showed strongest growth with sales of ¥24.1B, while Asia sales declined to ¥20.7B from ¥23.6B prior year. Japan remained the largest market at ¥41.6B (38.5% of total revenue). The shift in revenue mix toward higher-margin Organic Chemistry products was a key driver of profitability improvement.
Operating income surged 189.2% to ¥11.1B, with operating margin expanding dramatically from 3.6% to 10.3%. Gross profit increased to ¥32.6B with margin of 30.1%, while SG&A expenses of ¥21.5B remained well-controlled at 19.9% of revenue. The Organic Chemistry segment delivered segment profit of ¥10.3B at 18.7% margin (prior year ¥4.4B at 9.1% margin), representing the core driver of operating leverage improvement. Inorganic Chemistry segment profit improved to ¥3.7B at 7.4% margin from ¥1.9B at 3.6% margin.
Ordinary income of ¥13.2B exceeded operating income by ¥2.1B, reflecting net non-operating income contribution. Major components included FX gains of ¥1.9B, equity method income of ¥0.9B, and dividend income of ¥0.2B, partially offset by interest expense of ¥0.6B. Non-operating income represented 3.0% of revenue and contributed approximately 19% to ordinary income.
Net income reached ¥9.6B (421.6% YoY increase), with effective tax rate of 20.5% on profit before tax of ¥12.1B. Extraordinary losses of ¥1.1B included impairment losses of ¥0.4B, tempering the net income increase relative to ordinary income. The 27% gap between ordinary income (¥13.2B) and net income (¥9.6B) was primarily attributable to tax expense (¥2.5B) and extraordinary losses (¥1.1B). This represents a revenue-up/profit-up pattern with operating leverage expansion driving disproportionate profit growth relative to modest revenue gains.
The Organic Chemistry segment generated revenue of ¥55.4B (51.2% of total) with operating income of ¥10.3B and margin of 18.7%, establishing it as the core business and primary profit contributor. This represents substantial improvement from prior year segment profit of ¥4.4B at 9.1% margin, indicating significant operating leverage expansion. The Inorganic Chemistry segment produced revenue of ¥49.6B (45.9% of total) with operating income of ¥3.7B and margin of 7.4%, improving from prior year profit of ¥1.9B at 3.6% margin. The material 11.3pt margin differential between segments (Organic Chemistry 18.7% vs. Inorganic Chemistry 7.4%) highlights the value creation concentration in Organic Chemistry operations. The Other segment contributed ¥3.1B revenue with ¥0.5B operating income. Corporate/unallocated costs were ¥3.5B. Segment disclosures noted impairment losses of ¥0.2B in Organic Chemistry and ¥0.2B in Inorganic Chemistry as non-recurring factors.
[Profitability] ROE 7.9% represents improvement in return profile, with net profit margin of 8.9% expanding substantially from approximately 1.7% prior year, and operating margin of 10.3% improving 670bp from 3.6% YoY. The DuPont analysis reveals EBIT margin expansion as the dominant ROE driver, with net profit margin of 8.9%, asset turnover of 0.456x, and equity multiplier of 1.96x combining to deliver the 7.9% ROE. Tax burden ratio of 0.795 and interest burden ratio of 1.089 indicate favorable tax and capital structure effects. Gross profit margin of 30.1% and SG&A ratio of 19.9% reflect effective cost management. [Cash Quality] Cash and deposits of ¥35.0B provide substantial liquidity, with short-term interest-bearing debt coverage of 1.94x. Working capital efficiency shows concerning trends with inventory days of 410 and receivables days of 108, resulting in cash conversion cycle of 444 days. [Investment Efficiency] Asset turnover of 0.456x indicates room for improvement in asset utilization. [Financial Health] Equity ratio of 51.1% provides solid financial stability, current ratio of 315.8% and quick ratio of 225.0% indicate strong liquidity position, while debt-to-equity ratio of 0.96x and debt-to-capital ratio of 36.4% represent moderate leverage. Interest-bearing debt totals ¥69.2B (¥18.0B short-term, ¥51.1B long-term), with financial leverage of 1.96x remaining within reasonable bounds.
Cash and deposits increased ¥10.0B YoY to ¥35.0B, representing significant cash accumulation aligned with the ¥9.6B net income generation. The 40.1% increase in cash position suggests positive operating cash generation, though detailed cash flow statement data is not available for quarterly reporting. Working capital shows mixed signals, with trade payables of ¥15.2B providing ¥0.9B increase in supplier financing, partially offset by inventory expansion to ¥45.8B and trade receivables of ¥32.0B. The substantial inventory position (410 days inventory outstanding) and extended receivables collection (108 days sales outstanding) indicate working capital intensity that may constrain cash generation efficiency. Property, plant and equipment increased ¥6.9B to ¥53.4B, suggesting ongoing capital investment activity. The strong cash coverage of short-term liabilities at 1.94x and robust current ratio of 315.8x provide adequate financial flexibility. Investment securities holdings of ¥13.0B increased ¥1.6B, contributing to asset diversification. Defined benefit pension liabilities of ¥9.9B represent a notable long-term obligation.
Ordinary income of ¥13.2B versus operating income of ¥11.1B shows non-operating net contribution of approximately ¥2.1B, representing 19% of ordinary income. This comprises primarily FX gains of ¥1.9B, equity method income of ¥0.9B, and dividend income of ¥0.2B, partially offset by interest expense of ¥0.6B. Non-operating income represents 3.0% of revenue, with FX gains accounting for 1.7% of revenue and constituting a significant but potentially volatile component. The equity method income suggests value creation from investee companies. Extraordinary losses of ¥1.1B included impairment losses of ¥0.4B on buildings and land in both segments, representing non-recurring negative factors. The substantial divergence between operating income growth (+189.2%) and net income growth (+421.6%) reflects favorable tax effects and the leverage effect of improved profitability on bottom-line returns. While operating margins demonstrate fundamental business improvement, the material contribution from FX gains (14% of ordinary income) indicates earnings contain non-operational elements. The extended working capital cycle (444 days CCC) and inventory levels warrant monitoring for potential future impacts on cash-backed earnings quality.
Full-year FY2025 guidance projects revenue of ¥154.5B (+6.4% YoY), operating income of ¥17.0B (+62.2% YoY), ordinary income of ¥18.0B (+58.0% YoY), and net income of ¥13.0B. Q3 cumulative progress stands at 69.9% for revenue, 65.2% for operating income, 73.1% for ordinary income, and 73.9% for net income against full-year targets. Operating income and ordinary income progress rates trail the standard 75% benchmark for Q3, suggesting conservative guidance or potential back-end loaded performance expectations. Revenue progress of 69.9% is slightly below the 75% standard but within reasonable range given seasonality. The company forecasts full-year EPS of ¥339.74 and annual dividend of ¥90. Q3 cumulative operating margin of 10.3% implies full-year operating margin guidance of 11.0%, indicating expectation for continued margin strength in Q4. The guidance maintains prior forecasts without revision, suggesting management confidence in achieving targets. No order backlog or contract liability data is disclosed to assess forward revenue visibility.
Annual dividend forecast of ¥90 per share represents the company's shareholder return commitment. Based on full-year net income guidance of ¥13.0B (EPS ¥339.74) and 38.3M average shares outstanding, the payout ratio calculates to approximately 26.5%, indicating conservative capital allocation with substantial earnings retention. Using Q3 cumulative net income of ¥9.6B and current dividend forecast, the payout ratio approximates 35.7%, both figures suggesting sustainable dividend policy with ample coverage. Cash reserves of ¥35.0B and strong liquidity metrics (current ratio 315.8%) provide additional support for dividend sustainability. No share buyback activity is disclosed in the available data. The total return ratio equals the payout ratio at approximately 26.5-35.7% given absence of buybacks, indicating room for potential enhancement of shareholder returns through either dividend increases or capital repurchases while maintaining financial flexibility.
Working capital efficiency deterioration represents the most quantifiable risk, with inventory days of 410, receivables days of 108, and cash conversion cycle of 444 days indicating substantial cash tied up in operations. Inventory of ¥45.8B (42.4% of revenue) creates exposure to obsolescence risk and potential write-downs, particularly given product mix shifts between segments. Product market dynamics affecting segment profitability show concentration risk, with Organic Chemistry segment contributing ¥10.3B of ¥11.1B total operating income (93% of profit from 51% of revenue), creating vulnerability to demand fluctuations in this segment. Foreign exchange volatility poses material risk given ¥1.9B FX gains contributed 14% of ordinary income this period; reversal of yen weakness could significantly impact profitability and reduce non-operating income contribution.
[Industry Position] (Reference - Proprietary Analysis)
The company's financial metrics show mixed positioning relative to manufacturing industry medians. Profitability metrics demonstrate competitive strength: ROE of 7.9% exceeds the industry median of 5.8% (2025-Q3, n=105), operating margin of 10.3% surpasses the industry median of 8.9%, and net profit margin of 8.9% significantly exceeds the industry median of 6.5%. Revenue growth of 2.5% aligns closely with industry median of 2.8%, indicating in-line top-line performance. Financial health metrics reveal solid positioning with equity ratio of 51.1% below the more conservative industry median of 63.8%, while current ratio of 315.8% substantially exceeds the industry median of 2.87x, demonstrating superior liquidity. Return on assets of 4.1% (calculated) exceeds industry median of 3.4%. However, efficiency metrics present concerns: asset turnover of 0.456x falls below the industry median of 0.56, and working capital metrics significantly lag with inventory turnover of 410 days far exceeding industry median of 112 days and receivables turnover of 108 days above industry median of 85 days. The company's financial leverage of 1.96x exceeds industry median of 1.53x, reflecting somewhat higher balance sheet leverage. Overall, the company demonstrates strong profitability and liquidity relative to manufacturing peers but faces structural challenges in working capital efficiency and asset turnover that warrant operational focus.
(Industry: Manufacturing (n=105), Comparison: 2025-Q3 period, Source: Proprietary analysis)
Operating leverage expansion driving margin improvement represents the most significant structural development, with operating margin improving 670bp to 10.3% and Organic Chemistry segment margin reaching 18.7% from 9.1% prior year, indicating successful product mix shift and cost management initiatives that could sustain elevated profitability levels if demand conditions remain supportive. Working capital management emerges as the critical operational priority, with cash conversion cycle of 444 days, inventory days of 410, and the ¥45.8B inventory position (42.4% of revenue) creating both a constraint on cash generation and an opportunity for significant improvement; successful inventory optimization could unlock substantial cash flow enhancement and improve return metrics. The earnings composition shows meaningful contribution from non-operational sources, with FX gains of ¥1.9B contributing 14% of ordinary income and equity method income adding ¥0.9B, suggesting profit sustainability depends on both continued operational improvement and stability in currency and investment income streams, with potential volatility in these components affecting year-over-year comparisons in future periods.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.